<DOC>
	<DOCNO>NCT00002701</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Bone marrow transplantation may able replace immune cell destroy chemotherapy kill tumor cell . It yet know regimen combination chemotherapy without bone marrow transplantation effective treating promyelocytic leukemia PURPOSE : Randomized phase III trial compare effectiveness different combination chemotherapy regimens without bone marrow transplantation treat patient promyelocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Bone Marrow Transplantation Treating Patients With Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete remission ( CR ) rate patient acute promyelocytic leukemia treat induction comprise tretinoin ( ATRA ) idarubicin ( IDA ) . - Determine presence promyelocyte-retinoic acid receptor alpha ( PML-RARa ) transcript use polymerase chain reaction ( PCR ) patient CR 3 sequential consolidation regimens comprise cytarabine ( ARA-C ) plus IDA , follow mitoxantrone plus etoposide , IDA , ARA-C , thioguanine . - Determine percentage patient complete protocol , include PML-RARa-positive patient treat post-consolidation bone marrow transplantation ( BMT ) PML-RARa-negative patient treat maintenance comprise mercaptopurine ( MP ) plus methotrexate ( MTX ) v ATRA v MP plus MTX alternate ATRA v observation . - Compare disease-free survival ( DFS ) overall survival patient treat regimen . - Determine rate type grade 4 toxicity , treatment-related mortality , time granulocyte platelet recovery associate phase treatment patient . - Determine DFS overall survival PML-RARa-positive patient ineligible BMT treat maintenance comprise MP plus MTX alternate ATRA . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . - Induction : Patients receive oral tretinoin ( ATRA ) twice daily begin day 1 continue 30-90 day idarubicin ( IDA ) IV 15 minute day 2 , 4 , 8 . ATRA discontinue day 90 presence complete remission ( CR ) day 30 60 , unacceptable toxicity , disease progression absence least partial remission day 60 . Patients achieve CR induction proceed consolidation . - Consolidation : - First consolidation : Within 2 week achieve CR , patient receive cytarabine ( ARA-C ) IV 6 hour follow 3 hour later IDA IV 15 minute day 1-4 . - Second consolidation : Within 4-6 week initiation first consolidation , patient receive mitoxantrone IV 30 minute etoposide IV 1 hour ( begin 12 hour initiation mitoxantrone infusion ) day 1-5 . - Third consolidation : Within 4-6 week initiation second consolidation , patient receive ARA-C subcutaneously every 8 hour oral thioguanine every 8 hour day 1-5 IDA IV 15 minute day 1 . Patients proceed group A promyelocyte-retinoic acid receptor alpha ( PML-RARa ) -negative recovery third consolidation . Patients proceed allogeneic bone marrow transplantation ( BMT ) group B PML-RARa-positive , achieve CR , age 55 , HLA-A , -B , -DR identical , chronic myelomonocytic leukemia nonreactive , family donor recovery third consolidation . Patients proceed autologous BMT group B PML-RARa-positive , achieve CR , identical family donor age 55 recovery third consolidation . Patients proceed arm III group A PML-RARa-positive ineligible BMT recovery third consolidation . - Group A ( maintenance ) : Patients stratify accord participate center initial white blood cell count . Patients randomize 1 4 treatment arm . - Arm I : Patients receive oral mercaptopurine ( MP ) daily oral methotrexate ( MTX ) weekly . - Arm II : Beginning 3 month recovery third consolidation , patient receive oral ATRA day 1-15 . Treatment arm I II continue every 3 month 2 year absence disease progression unacceptable toxicity . - Arm III : Patients receive 1 course arm I treatment , alternate 1 course arm II treatment . Alternating treatment continue every 3 month 2 year absence disease progression unacceptable toxicity . - Arm IV : Patients undergo observation . - Group B : Eligible patient receive condition comprise cyclophosphamide ( CTX ) IV 2 day follow total body irradiation oral busulfan day -9 -6 CTX day -5 -2 . Autologous allogeneic bone marrow infuse day 0 ( within 4 month initiation third consolidation ) . Quality life assess baseline , induction , consolidation regimen , every 3 month begin treatment group A B . Patients follow every 3 month . PROJECTED ACCRUAL : A total 750 patient accrue study within 7.5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute promyelocytic leukemia Must promyelocyteretinoic acid receptor alpha transcript disease presentation PATIENT CHARACTERISTICS : Age : 16 74 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) AST great 3 time ULN Alkaline phosphatase great 3 time ULN Renal : Creatinine great 2.5 mg/dL Cardiovascular : No cardiac contraindication anthracycline chemotherapy Other : No active serious infection control antibiotic No severe concurrent psychiatric disease No malignancy except basal cell carcinoma Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent cytotoxic chemotherapy Endocrine therapy : Prior corticosteroid leukemia allow Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No prior antileukemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
</DOC>